Patents Assigned to GENPHARMA CONSULTORIA FARMACEUTICA E GENETICA LTDA.
  • Use of telocinobufagin as an analgesic in the treatment of acute and chronic pains
    Patent number: 8541395
    Abstract: The present invention is directed to the use of telocinobufagin, or its pharmaceutically acceptable derivatives, in the manufacture of a medicament for the treatment or prevention of acute and chronic pains. The present invention also refers to a pharmaceutical composition comprising an effective amount of telocinobufagin; also provides a method to induce analgesia in response to acute and chronic pains that comprehends administering an effective amount of telocinobufagin to human beings or animals. According to the outcomes of in vivo assays, telocinobufagin is more potent than morphine, though without presenting the known side effects of opioids. In addition, in vivo and in vitro essays showed that TBC does not present cardiotoxicity.
    Type: Grant
    Filed: May 26, 2010
    Date of Patent: September 24, 2013
    Assignees: Cristalia Produtos Quimicos Farmaceuticos Ltda., Genpharma Consultoria Farmaceutica E Genetica Ltda.
    Inventors: Krishnamurti De Morais Carvalho, Dòris Maria Fernandes Carvalho, Maria Denise Fernandes Carvalho, Ogari de Castro Pacheco, Roberto Carlos Debom Moreira
  • USE OF TELOCINOBUFAGIN AS AN ANALGESIC IN THE TREATMENT OF ACUTE AND CHRONIC PAINS; PHARMACEUTICAL COMPOSITION CONTAINING TELOCINOBUFAGIN AND ITS USE
    Publication number: 20120077788
    Abstract: The present invention is directed to the use of telocinobufagin, or its pharmaceutically acceptable derivatives, in the manufacture of a medicament for the treatment or prevention of acute and chronic pains. The present invention also refers to a pharmaceutical composition comprising an effective amount of telocinobufagin; also provides a method to induce analgesia in response to acute and chronic pains that comprehends administering an effective amount of telocinobufagin to human beings or animals. According to the outcomes of in vivo assays, telocinobufagin is more potent than morphine, though without presenting the known side effects of opioids. In addition, in vivo and in vitro essays showed that TBC does not present cardiotoxicity.
    Type: Application
    Filed: May 26, 2010
    Publication date: March 29, 2012
    Applicants: GENPHARMA CONSULTORIA FARMACEUTICA E GENETICA LTDA., CRISTALIA PRODUTOS QUIMICOS FARMACEUTICOS LTDA.
    Inventors: Krishnamurti De Morais Carvalho, Dòris Maria Fernandes Carvalho, Maria Denise Fernandes Carvalho, Ogari de Castro Pacheco, Roberto Carlos Debom Moreira